安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- 2023 Essential Messages from ESC Guidelines
Regarding P2Y12 receptor inhibitor choice, prasugrel and ticagrelor are recommended in preference to clopidogrel and prasugrel should be considered in preference to ticagrelor for ACS patients who undergo PCI
- Khuyến cáo ESC 2023 - bvtgialai. vn
Ức chế P2Y12 Heparin không phân đoạn TLPT thấp (CABG) ĐMV thủ phạm nếu có chỉ định ©ESC 2023 ESC Guidelines for the management of acute coronary syndromes (European Heart Journal; 2023 – doi:10 1093 eurheartj ehad191) Khuyến cáo Mức BC
- 2023 European Society of Cardiology guidelines for the management of . . .
With respect to which potent P2Y 12 inhibitor to choose, the guidelines state that prasugrel should be considered in preference to ticagrelor for ACS patients who proceed to PCI (class IIa, LoE B) However, this preference for prasugrel is based on limited evidence, as we previously set out [ 9 ]
- ESC ACS Guidelines 2023 – The Cardiovascular
If patients presenting with ACS stop DAPT to undergo CABG, it is recommended they resume DAPT after surgery for at least 12 months I: C: Prasugrel should be considered in preference to ticagrelor for ACS patients who proceed to PCI IIa: B
- Comparison of Ticagrelor and Clopidogrel in Patients With Acute . . .
However, whether a potent P2Y12 inhibitor (ticagrelor) or a less potent one (clopidogrel) is more appropriate in patients with acute coronary syndrome (ACS) in the setting of high bleeding or ischemic risk is not clear
- 2023 Guidelines on Coronary Artery Disease: At a Glance
In elderly ACS patients with high bleeding risk, clopidogrel may be considered as a P2Y12 inhibitor c In patients at low ischemic risk and event-free after 3−6 months of DAPT, a single antiplatelet agent (a P2Y12 inhibitor) should be considered d
- 2023 ESC Guidelines for the management of acute coronary syndromes
This guideline provides a comprehensive overview of the management of patients presenting with Acute coronary syndrome (ACS) from the point of diagnosis and risk stratification at initial presentation, through to long-term management after the initial hospitalisation period
- 2023 ESC Guidelines on ACS: what is new in antithrombotic therapy?
Shorter DAPT regimens are to be considered for ACS patients without ischaemic events and not at high-ischaemic risk after 3–6 months (class IIa, LoE A), while 1 month DAPT in patients at high bleeding risk (class IIb, LoE B) and de-escalation of P2Y 12 inhibiting therapy (e g from prasugrel or ticagrelor to clopidogrel; class IIb, LoE A) may
|
|
|